This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Zacks Investment Ideas feature highlights: Kroger, General Mills and Johnson & Johnson
by Zacks Equity Research
Kroger, General Mills and Johnson & Johnson have been highlighted in this Investment Ideas article.
Sail Through Rough Waters With These 3 Low-Beta Stocks
by Derek Lewis
Even though low-beta stocks have a lower return potential, they're great shields against volatility. After all, defense wins ballgames.
Johnson & Johnson (JNJ) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Zacks.com users have recently been watching Johnson & Johnson (JNJ) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Johnson & Johnson (JNJ) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Johnson & Johnson (JNJ) closed at $163.20 in the latest trading session, marking a -0.1% move from the prior day.
Can AbbVie's (ABBV) New Drugs Make up for Lost Humira Sales?
by Zacks Equity Research
AbbVie's (ABBV) new drugs, Skyrizi and Rinvoq, are faring well, bolstered by approval in new indications. They are expected to drive revenues once Humira loses U.S. exclusivity in 2023.
Is Vanguard Dividend Appreciation ETF (VIG) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for VIG
Should Vanguard Value ETF (VTV) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for VTV
Why Low Volatility ETFs are Beating the Market
by Neena Mishra
We highlight 3 popular low and minimum volatility ETFs
The Zacks Analyst Blog Highlights UnitedHealth Group, Johnson & Johnson, Chevron, The Home Depot and AT&T
by Zacks Equity Research
UnitedHealth Group, Johnson & Johnson, Chevron, The Home Depot and AT&T are part of the Zacks top Analyst Blog.
Is iShares Core High Dividend ETF (HDV) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for HDV
Johnson & Johnson (JNJ) Stock Moves -0.61%: What You Should Know
by Zacks Equity Research
In the latest trading session, Johnson & Johnson (JNJ) closed at $165.70, marking a -0.61% move from the previous day.
Top Stock Reports for UnitedHealth, Johnson & Johnson, & Chevron
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including UnitedHealth Group Incorporated (UNH), Johnson & Johnson (JNJ) and Chevron Corporation (CVX).
Should iShares Russell 1000 Value ETF (IWD) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for IWD
Should Schwab U.S. LargeCap Value ETF (SCHV) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for SCHV
Should You Invest in the Fidelity MSCI Health Care Index ETF (FHLC)?
by Zacks Equity Research
Sector ETF report for FHLC
Is WisdomTree U.S. Quality Dividend Growth ETF (DGRW) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for DGRW
Merck (MRK) Resumes HIV Studies on Islatravir With Lower Dose
by Zacks Equity Research
Merck's (MRK) new phase III studies are set to evaluate a once-daily oral combination of doravirine and a lower dose of islatravir
Johnson & Johnson (JNJ) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Johnson & Johnson (JNJ) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Johnson & Johnson (JNJ) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Johnson & Johnson (JNJ) closed at $166.28, marking a -0.79% move from the previous day.
Defense Wins Ballgames; 3 Blue-Chip Stocks To Consider
by Derek Lewis
Due to their well-established nature and track records of success, these companies are positioned to weather a dark fiscal cloud better than most.
Beat the Market Like Zacks: Hargreaves Lansdown (HRGLY), Starbucks (SBUX), Johnson & Johnson (JNJ) in Focus
by Abhinab Dasgupta
Our time-tested methodologies were at work to help investors navigate the market well last week. Here are some of our accomplishments from last week.
Should iShares Core High Dividend ETF (HDV) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for HDV
Pharma Stock Roundup: J&J New Buyback Plan, CHMP Nod to PFE's BA.4, BA.5 Omicron Jab
by Kinjel Shah
J&J (JNJ) announces a new $5 billion stock buyback plan. CHMP recommends authorizing Pfizer's (PFE) Omicron BA.4 and BA.5 boosters in Europe.
Is WisdomTree U.S. Total Dividend ETF (DTD) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for DTD
Is iShares Core Dividend Growth ETF (DGRO) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for DGRO